Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab plus lenalidomide in follicular lymphoma, including randomized SC versus IV mosunetuzumab comparison
2023-507236-20-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Jul 2020
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of mosunetuzumab and lenalidomide in follicular lymphoma (FL) (3 arms), sponsored by Roche. Primary endpoints: Dose-limiting toxicity, Incidence, nature, and severity of adverse events and 6 more. Planned start Jul 2020; status: authorised.
02
Drugs
mosunetuzumablenalidomide
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2023-507236-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507236-20-00.